[{"address1": "301 Binney Street", "address2": "Suite 402", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 401 9975", "website": "https://www.synlogictx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.", "fullTimeEmployees": 6, "companyOfficers": [{"maxAge": 1, "name": "Mr. Antoine  Awad", "age": 43, "title": "Principal Executive Officer & COO", "yearBorn": 1980, "fiscalYear": 2022, "totalPay": 566555, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Timothy K. Lu M.D., Ph.D.", "age": 42, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1981, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary Beth Dooley", "age": 42, "title": "VP, Head of Finance and Principal Financial Officer & Principal Accounting Officer", "yearBorn": 1981, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brendan St. Amant", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ajay  Munshi", "title": "Vice President of Corporate Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam J. Thomas", "title": "Chief People Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Caroline B. Kurtz Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Molly  Harper", "age": 46, "title": "Chief Business Officer", "yearBorn": 1977, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Neal  Sondheimer M.D., Ph.D.", "title": "VP & Head of Clinical", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mylene  Perreault Ph.D.", "title": "VP & Head of Research", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.87, "open": 1.8254, "dayLow": 1.78, "dayHigh": 1.845, "regularMarketPreviousClose": 1.87, "regularMarketOpen": 1.8254, "regularMarketDayLow": 1.78, "regularMarketDayHigh": 1.845, "beta": 1.065, "forwardPE": -17.9, "volume": 20551, "regularMarketVolume": 20551, "averageVolume": 139450, "averageVolume10days": 30790, "averageDailyVolume10Day": 30790, "marketCap": 20848130, "fiftyTwoWeekLow": 0.234, "fiftyTwoWeekHigh": 5.708, "priceToSalesTrailing12Months": 6.1845536, "fiftyDayAverage": 1.8286, "twoHundredDayAverage": 1.94467, "currency": "USD", "enterpriseValue": -9622911, "floatShares": 2266618, "sharesOutstanding": 11647000, "sharesShort": 35580, "sharesShortPriorMonth": 22580, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0031, "heldPercentInsiders": 0.15692, "heldPercentInstitutions": 0.70464, "shortRatio": 0.77, "shortPercentOfFloat": 0.0034, "impliedSharesOutstanding": 11647000, "bookValue": 4.643, "priceToBook": 0.38552657, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -57282000, "trailingEps": -8.81, "forwardEps": -0.1, "lastSplitFactor": "1:7", "lastSplitDate": 1503878400, "enterpriseToRevenue": -2.855, "enterpriseToEbitda": 0.181, "52WeekChange": 2.3209648, "SandP52WeekChange": 0.23099434, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SYBX", "underlyingSymbol": "SYBX", "shortName": "Synlogic, Inc.", "longName": "Synlogic, Inc.", "firstTradeDateEpochUtc": 1443619800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "30bbb3c7-ab0a-33b2-91a8-e57d2c890111", "messageBoardId": "finmb_268899196", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.79, "targetHighPrice": 1.0, "targetLowPrice": 1.0, "targetMeanPrice": 1.0, "targetMedianPrice": 1.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 47746000, "totalCashPerShare": 4.099, "ebitda": -53203000, "totalDebt": 17275000, "quickRatio": 2.34, "currentRatio": 2.446, "totalRevenue": 3371000, "debtToEquity": 40.499, "revenuePerShare": 0.518, "returnOnAssets": -0.36988, "returnOnEquity": -0.91457003, "freeCashflow": -22271250, "operatingCashflow": -51614000, "revenueGrowth": 25.123, "grossMargins": 1.0, "operatingMargins": -3.8429, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-01"}]